In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.
 

Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
 

French Biotech In Focus: Amid a global biotech funding boom last year, French biotech saw a rise in the number of high-value financing rounds while its firms adopt savvy licensing strategies.
 

The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
 

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
 

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
 

The world’s aging, increasingly tech-savvy population has created demand for device and digital health solutions that enable people to live longer, healthier, more independent lives.
 

With its lateral flow at-home tests for ferritin, thyroid function and ovarian reserves, Swiss medtech firm Bloom Diagnostics thinks it has seen the future of consumer healthcare.